Systematic Review: Characteristics and Preclinical Uses of Bladder Cancer Cell Lines

por Zuiverloon, Tahlita C.M., de Jong, Florus C., Costello, James C., Theodorescu, Dan
Publicado 2018

Role of Bladder Cancer Metabolic Reprogramming in the Effectiveness of Immunotherapy

por Scholtes, Mathijs P., de Jong, Florus C., Zuiverloon, Tahlita C. M., Theodorescu, Dan
Publicado 2021

Improving Anti-PD-1/PD-L1 Therapy for Localized Bladder Cancer

por de Jong, Florus C., Rutten, Vera C., Zuiverloon, Tahlita C. M., Theodorescu, Dan
Publicado 2021

Open versus minimal invasive radical cystectomy

por van Diepen, Danielle C., Zuiverloon, Tahlita C. M., Klaver, Sjoerd O., Boormans, Joost L.
Publicado 2020

Sewage surveillance system using urological wastewater: Key to COVID-19 monitoring?

por de Jong, Florus C., GeurtsvanKessel, Corine H., Molenkamp, Richard, Bangma, Chris H., Zuiverloon, Tahlita C.M.
Publicado 2023

Molecular Biomarkers of Response to PD-1/ PD-L1 Immune Checkpoint Blockade in Advanced Bladder Cancer(1)

por Tu, Megan M., Ng, Terry L., De Jong, Florus C., Zuiverloon, Tahlita C.M., Fazzari, Francesco G.T., Theodorescu, Dan
Publicado 2019

The CHASIT study: sequential chemo-immunotherapy in patients with locally advanced urothelial cancer – a non-randomized phase II clinical trial

por Rutten, V. C., Salhi, Y., Robbrecht, G. J., de Wit, R., van Leenders, G. J.L.H., Zuiverloon, T. C.M., Boormans, J. L.
Publicado 2023

Biomarker-Oriented Therapy in Bladder and Renal Cancer

por Scholtes, Mathijs P., Alberts, Arnout R., Iflé, Iris G., Verhagen, Paul C. M. S., van der Veldt, Astrid A. M., Zuiverloon, Tahlita C. M.
Publicado 2021

Artificial Intelligence in Digital Pathology for Bladder Cancer: Hype or Hope? A Systematic Review

por Khoraminia, Farbod, Fuster, Saul, Kanwal, Neel, Olislagers, Mitchell, Engan, Kjersti, van Leenders, Geert J. L. H., Stubbs, Andrew P., Akram, Farhan, Zuiverloon, Tahlita C. M.
Publicado 2023

Analysis of molecular intra-patient variation and delineation of a prognostic 12-gene signature in non-muscle invasive bladder cancer; technology transfer from microarrays to PCR

por Dyrskjøt, L, Reinert, T, Novoradovsky, A, Zuiverloon, T C M, Beukers, W, Zwarthoff, E, Malats, N, Real, F X, Segersten, U, Malmström, P-U, Knowles, M, Hurst, C, Sorge, J, Borre, M, Ørntoft, T F
Publicado 2012

Intravesical BCG in patients with non-muscle invasive bladder cancer induces trained immunity and decreases respiratory infections

por van Puffelen, Jelmer H, Novakovic, Boris, van Emst, Liesbeth, Kooper, Denise, Zuiverloon, Tahlita C M, Oldenhof, Ursula T H, Witjes, J Alfred, Galesloot, Tessel E, Vrieling, Alina, Aben, Katja K H, Kiemeney, Lambertus A L M, Oosterwijk, Egbert, Netea, Mihai G, Boormans, Joost L, van der Heijden, Antoine G, Joosten, Leo A B, Vermeulen, Sita H
Publicado 2023

The clonal relation of primary upper urinary tract urothelial carcinoma and paired urothelial carcinoma of the bladder

por van Doeveren, Thomas, Nakauma‐Gonzalez, Jose A., Mason, Andrew S., van Leenders, Geert J. L. H., Zuiverloon, Tahlita C. M., Zwarthoff, Ellen C., Meijssen, Isabelle C., van der Made, Angelique C., van der Heijden, Antoine G., Hendricksen, Kees, van Rhijn, Bas W. G., Voskuilen, Charlotte S., van Riet, Job, Dinjens, Winand N. M., Dubbink, Hendrikus J., van de Werken, Harmen J. G., Boormans, Joost L.
Publicado 2020